Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05555251
Title Phase 1/2a Open-label Trial of BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BioInvent International AB

Advanced Solid Tumor

stomach cancer

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Her2-receptor positive breast cancer


BI-1607 + Trastuzumab

Age Groups: adult | senior
Covered Countries ESP | DEU

No variant requirements are available.